Citations

Clear

3942 citation(s) found for "To, Van".

TOPACIO/Keynote-162 (NCT02657889): A phase 1/2 study of niraparib + pembrolizumab in patients (pts) with advanced triple-negative breast cancer or recurrent ovarian cancer (ROC)—Results from ROC cohort.
Konstantinopoulos, Panagiotis A. , Waggoner, Steven , Vidal, Gregory A. , Mita, Monica , Holloway, Robert W. , Le, Linda Van, Sachdev, Jasgit C. , Chapman‐Davis, Eloise , Colón‐Otero, Gerardo , Penson, Richard T. , Matulonis, Ursula A. , Kim, Young B., Dezube, Bruce J., Wang, Jing Y., Buerstatte, Nathan, Arora, Sujata, Münster, Pamela N. , Munster, Pamela , Konstantinopoulos, Panagiotis A , Fleming, Gini F. , Moore, Kathleen N. , Swisher, Elizabeth M.

Mayo Clinic

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: 106-106

10.1200/jco.2018.36.15_suppl.106 Get It

Subgroup analysis of elderly patients treated within the randomized phase 3 doxorubicin versus doxorubicin plus evofosfamide (SARC021) trial.
Younger, Eugenie , Pápai, Zsuzsanna , Tine, Brian Andrew Van, Attia, Steven , Lu, Yao , Schöffski, Patrick , Tap, William D. , Jones, Robin L. , Jones, Robin L , Ballman, Karla V. , Reinke, Denise K.

Mayo Clinic

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: 11575-11575

10.1200/jco.2018.36.15_suppl.11575 Get It

A phase II study of pazopanib with oral topotecan in patients with metastatic and non-resectable soft tissue and bone sarcomas.
Agulnik, Mark , Mohindra, Nisha , Attia, Steven , Rademaker, Alfred , Abbinanti, Susan, Cehic, Rasima, Humphreys, Catherine , Okuno, Scott H. , Tine, Brian Andrew Van, Milhem, Mohammed , Robinson, Steven I. , Humphreys, Catherine, Prudner, Bethany Cheree

Mayo Clinic

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: 11550-11550

10.1200/jco.2018.36.15_suppl.11550 Get It

Phase 1b/2 study of olaratumab plus gemcitabine and docetaxel for the treatment of advanced soft tissue sarcoma (STS) (ANNOUNCE 2): Phase 1b results.
Villalobos, Víctor M. , Tine, Brian Andrew Van, Dickson, Mark A. , Cronier, Damien M., Attia, Steven , Redondo, Andrés , Schwartz, Gary K. , Chmielowski, Bartosz , Peterson, Patrick M. , Wright, Jennifer

Mayo Clinic

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: 11542-11542

10.1200/jco.2018.36.15_suppl.11542 Get It

A phase 2 biomarker trial of combination cediranib and olaparib in relapsed platinum (plat) sensitive and plat resistant ovarian cancer (ovca).
Barry, William T., Wenham, Robert M. , Hendrickson, Andrea E. Wahner , Armstrong, Deborah K. , Chan, Nancy , Lee, Jung‐Min , Penson, Richard T. , Cristea, Mihaela , Abbruzzese, James L. , Matsuo, Koji , Olawaiye, Alexander , Farooq, Sarah , Kohn, Elise C. , Matulonis, Ursula A. , Liu, Joyce F. , Cohn, David E. , Swisher, Elizabeth M. , Van Allen, Eliezer M , Shapiro, Geoffrey I. , Ivy, S. Percy

Mayo Clinic

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: 5519-5519

10.1200/jco.2018.36.15_suppl.5519 Get It

Clinical evaluation of germline polymorphisms (SNPs) associated with disease response to capecitabine in metastatic breast cancer (MBC) (TBCRC 015).
Evans, Patrick , Morrow, Phuong K. , Storniolo, Anna Maria , Forero‐Torres, Andres , Poznak, Catherine Van , Merkel, Douglas E., Dees, Elizabeth Claire , Hahn, Olwen, Hoffman, Philip C., Nanda, Rita , O’Donnell, Peter H. , Choudhury, Noura J. , Ingle, James N. , Mayer, Ingrid A. , Fleming, Gini F. , Olopade, Olufunmilayo I. , Cox, Nancy J.

Mayo Clinic

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: 1071-1071

10.1200/jco.2018.36.15_suppl.1071 Get It

A Prognostic Index to Identify the Risk of Developing Depression Symptoms Among U.S. Medical Students Derived From a National, Four-Year Longitudinal Study
Wittlin, Natalie M. , Yeazel, Mark W. , Burke, Sara E. , Cunningham, Brooke A. , Ryn, Michelle van , Dyrbye, Liselotte N. , van Ryn, Michelle , Hardeman, Rachel R. , Herrin, Jeph , Dovidio, John F. , Phelan, Sean M. , Shanafelt, Tait D.

Mayo Clinic

Academic Medicine | September 5, 2018 | Volume: 94 | Issue: 2 | Pages: 217-226

10.1097/acm.0000000000002437 | PMID 30188367 Get It

Purpose To determine baseline individual and school-related factors associated with increased risk of developing depression symptoms by year four (Y4) of medical school, and to develop a prognostic index that stratifies risk of developing depression symptoms (Depression-PI) among medical students. Method The authors analyzed data from 3,743 students (79% of 4,732) attending 49 U.S. medical schools who completed baseline (2010) and Y4 (2014) surveys. Surveys included validated scales measuring depression, stress, coping, and social support. The authors collected demographics and school characteristics and conducted multivariate analysis to identify baseline factors independently associated with Y4 depression symptoms. They used these factors to create a prognostic index for developing depression. They randomly divided the data into discovery (n = 2,455) and replication (n = 1,288) datasets and calculated c statistics ( c ). Results The authors identified eight independent prognostic factors for experiencing depression symptoms during training within the discovery dataset: age; race; ethnicity; tuition; and baseline depression symptoms, stress, coping behaviors, and social support. The Depression-PI stratified four risk groups. Compared with the low risk group, those in the intermediate, high, and very high risk groups had an odds ratio of developing depression of, respectively, 1.75, 3.98, and 9.19 ( c = 0.71). The replication dataset confirmed the risk groups. Conclusions Demographics; tuition; and baseline depression symptoms, stress, coping behaviors, and social support are independently associated with risk of developing depression during training among U.S. medical students. By stratifying students into four risk groups, the Depression-PI may allow for a tiered primary prevention approach.
International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease
Rhee, Frits van , Voorhees, Peter M. , Srkalović, Gordan , Ide, Makoto , Munshi, Nikhil C. , Schey, Stephen, Streetly, Matthew , Pierson, Sheila K. , Partridge, Helen , Shilling, Dustin, Stone, Katie , Greenway, Amy D, Ruth, Jason R., Lechowicz, Mary Jo , Jayanthan, Raj , Leitch, Heather A. , Pemmaraju, Naveen , Chadburn, Amy , Lim, Megan S. , Elenitoba‐Johnson, Kojo S.J. , Goodman, Aaron M. , Hoffmann, Christian , Zinzani, Pier Luigi , Ferrero, Simone , Terriou, Louis , Simpson, David , Rossi, Jean‐François, Yoshizaki, Kazuyuki , Oksenhendler, Éric , van Rhee, Frits , Wong, Raymond S M , Casper, Corey , Fajgenbaum, David C , Ferrero, Simone , Zinzani, Pier Luigi , Dispenzieri, Angela , Fosså, Alexander , Partridge, Helen L., Mukherjee, Sudipto , Chandrakasan, Shanmuganathan , Jaffe, Elaine S. , Krymskaya, Vera P. , Sato, Yasuharu , Wong, Raymond , Rossi, Jean‐François , Nasta, Sunita , Kurzrock, Razelle , Uldrick, Thomas S. , Casper, Corey , Fajgenbaum, David C. , Ide, Makoto , Lim, Megan S

Mayo Clinic

Blood | September 4, 2018 | Volume: 132 | Issue: 20 | Pages: 2115-2124

10.1182/blood-2018-07-862334 | PMID 30181172 Get It

Abstract Castleman disease (CD) describes a group of heterogeneous hematologic disorders with characteristic histopathological features. CD can present with unicentric or multicentric (MCD) regions of lymph node enlargement. Some cases of MCD are caused by human herpesvirus-8 (HHV-8), whereas others are HHV-8–negative/idiopathic (iMCD). Treatment of iMCD is challenging, and outcomes can be poor because no uniform treatment guidelines exist, few systematic studies have been conducted, and no agreed upon response criteria have been described. The purpose of this paper is to establish consensus, evidence-based treatment guidelines based on the severity of iMCD to improve outcomes. An international Working Group of 42 experts from 10 countries was convened by the Castleman Disease Collaborative Network to establish consensus guidelines for the management of iMCD based on published literature, review of treatment effectiveness for 344 cases, and expert opinion. The anti–interleukin-6 monoclonal antibody siltuximab (or tocilizumab, if siltuximab is not available) with or without corticosteroids is the preferred first-line therapy for iMCD. In the most severe cases, adjuvant combination chemotherapy is recommended. Additional agents are recommended, tailored by disease severity, as second- and third-line therapies for treatment failures. Response criteria were formulated to facilitate the evaluation of treatment failure or success. These guidelines should help treating physicians to stratify patients based on disease severity in order to select the best available therapeutic option. An international registry for patients with CD (ACCELERATE, #NCT02817997) was established in October 2016 to collect patient outcomes to increase the evidence base for selection of therapies in the future.
Systematic review of the screening, diagnosis, and management of ADHD in children with epilepsy. Consensus paper of the Task Force on Comorbidities of the ILAE Pediatric Commission
Auvin, Stéphane , Donald, Kirsten A. , Hartmann, Hans , Valente, Kette D. , Bogaert, Patrick Van , Cross, J. Helen , Ōsawa, Makiko, Kanemura, Hideaki , Aihara, Masao, Guerreiro, Marilisa M. , Vinayan, Kollencheri Puthenveettil , Smith, Mary Lou , Carmant, Lionel, Kerr, Michael , Dunn, David , Wilmshurst, Jo M. , Berl, Madison , Kanemura, Hideaki , Wilmshurst, Jo M , Auvin, Stéphane , Cross, Helen J , Valente, Kette , Wirrell, Elaine , Berl, Madison M. , Samia, Pauline , Hermann, Bruce P.

Mayo Clinic

Epilepsia | September 4, 2018 | Volume: 59 | Issue: 10 | Pages: 1867-1880

10.1111/epi.14549 | PMID 30178479 Get It

SummaryAttention‐deficit/hyperactivity disorder (ADHD) is a common and challenging comorbidity affecting many children with epilepsy. A working group under the International League Against Epilepsy (ILAE) Pediatric Commission identified key questions on the identification and management of ADHD in children with epilepsy. Systematic reviews of the evidence to support approaches to these questions were collated and graded using criteria from the American Academy of Neurology Practice Parameter. Preferred Reporting Items for Systematic Reviews and Meta‐Analyses (PRISMA) requirements were followed, with PROSPERO registration (CRD42018094617). No increased risk of ADHD in boys with epilepsy compared to girls with epilepsy was found (Level A). Valproate use in pregnancy is associated with inattentiveness and hyperactivity in offspring (1 class I study), and children with intellectual and developmental disabilities are at increased risk of ADHD (Level A). Impact of early seizure onset on development of ADHD was unclear (Level U), but more evident with poor seizure control (Level B). ADHD screening should be performed from 6 years of age, or at diagnosis, and repeated annually (Level U) and reevaluated after change of antiepileptic drug (AED) (Level U). Diagnosis should involve health practitioners with expert training in ADHD (Level U). Use of the Strength and Difficulties Questionnaire screening tool is supported (Level B). Formal cognitive testing is strongly recommended in children with epilepsy who are struggling at school (Level U). Behavioral problems are more likely with polytherapy than monotherapy (Level C). Valproate can exacerbate attentional issues in children with childhood absence epilepsy (Level A). Methylphenidate is tolerated and effective in children with epilepsy (Level B). Limited evidence supports that atomoxetine is tolerated (Level C). Multidisciplinary involvement in transition and adult ADHD clinics is essential (Level U). In conclusion, although recommendations could be proposed for some of the study questions, this systematic review highlighted the need for more comprehensive and targeted large‐population prospective studies.